Valuation Processa Pharmaceuticals, Inc. OTC Markets
Stocks
PCSA
US74275C4033
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.100 USD | -38.38% |
|
-.--% | - |
| 07-30 | Processa Pharmaceuticals, Inc. acquired Vidya Therapeutics, Inc. for approximately $320 million. | CI |
| 07-30 | Processa Pharmaceuticals, Inc. - M&A Call |
Company Valuation: Processa Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 69.68 | 77.01 | 17.59 | 8.242 | 2.887 | 6.525 |
| Change | - | 10.51% | -77.16% | -53.15% | -64.97% | 126% |
| Enterprise Value (EV) 1 | 54.59 | 60.59 | 11.32 | 3.686 | 1.769 | 0.9885 |
| Change | - | 10.98% | -81.32% | -67.43% | -51.99% | -44.14% |
| P/E | -2.6x | -6.57x | -0.65x | -0.79x | -0.23x | -0.28x |
| PBR | 4.08x | 3.02x | 2.36x | 1.72x | 1.93x | 1.33x |
| PEG | - | 0.1x | -0x | 0x | 0x | 0x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -9.69x | -5.62x | -0.58x | -0.32x | -0.15x | -0.07x |
| EV / EBIT | -8.48x | -5.24x | -0.56x | -0.32x | -0.15x | -0.07x |
| EV / FCF | -237x | -14.5x | -3.82x | -0.9x | -0.3x | -0.15x |
| FCF Yield | -0.42% | -6.92% | -26.2% | -111% | -331% | -663% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1,269 | -373 | -851.2 | -212 | -96.82 | -10.36 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -5.633 | -10.78 | -19.47 | -11.46 | -12.05 | -13.99 |
| EBIT 1 | -6.437 | -11.57 | -20.26 | -11.46 | -12.05 | -13.99 |
| Net income 1 | -14.41 | -11.43 | -27.42 | -11.12 | -11.85 | -13.56 |
| Net Debt 1 | -15.09 | -16.42 | -6.274 | -4.556 | -1.118 | -5.537 |
| Reference price 2 | 3,297.500 | 2,450.000 | 550.000 | 167.300 | 22.095 | 2.880 |
| Nbr of stocks (in thousands) | 21.1 | 31.4 | 32 | 49.3 | 131 | 2,266 |
| Announcement Date | 25/03/21 | 30/03/22 | 30/03/23 | 29/03/24 | 20/03/25 | 18/03/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.55x | 8.04x | 24.82x | 0.05% | 55.2B | |
| 20.93x | 6.45x | 14.11x | 1.52% | 55.6B | |
| -18.58x | 4.52x | -7.92x | -.--% | 23.51B | |
| -40.37x | 12.81x | -37.74x | -.--% | 22.35B | |
| 25.93x | 5.08x | 13.45x | -.--% | 20.6B | |
| 24.39x | 4.74x | 15.42x | -.--% | 17.45B | |
| -762.09x | 36.16x | -4070.99x | -.--% | 15.16B | |
| 17.41x | 5.04x | 11.76x | -.--% | 13.91B | |
| 41.47x | 16.7x | 43.01x | 0.09% | 13.74B | |
| Average | -73.15x | 11.06x | -443.79x | 0.18% | 26.39B | |
| Weighted average by Cap. | -34.37x | 9.39x | -249.70x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PCSA Stock
- PCSA Stock
- Valuation Processa Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
